Hoth Therapeutics (HOTH) Stock Price, News & Analysis

Company Overview

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis. The company holds exclusive worldwide licenses for a range of small molecules and biological compounds sourced from leading academic institutions and research organizations. By advancing these assets through preclinical studies and early-stage clinical trials, Hoth aims to validate therapeutic potential and move products toward regulatory milestones and eventual commercialization.

Founded in 2018 and headquartered in New York, Hoth Therapeutics operates through strategic collaborations with universities, entrepreneurial biotech firms and contract research organizations. The company’s management team brings expertise in drug development, regulatory affairs and commercial strategy, positioning Hoth to navigate the complexities of clinical advancement and market entry. With a focus on specialized delivery technologies and precision formulations, Hoth seeks to address unmet medical needs and deliver innovative treatment options to patients worldwide.

Key Stats

• Today's Range: $1.31 to $1.37
• 50-Day Range: $1.16 to $1.49
• 52-Week Range: $0.65 to $3.80
• Volume: 568,340 shs
• Average Volume: 1.41 million shs
• Market Capitalization: $17.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Hoth Therapeutics Stock Analysis - MarketRank™

Hoth Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 590th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Hoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Hoth Therapeutics has a consensus price target of $4.00, representing about 200.8% upside from its current price of $1.33.

Amount of Analyst Coverage

Hoth Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hoth Therapeutics are expected to grow in the coming year, from ($1.36) to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hoth Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hoth Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hoth Therapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.94% of the float of Hoth Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Hoth Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hoth Therapeutics has recently decreased by 16.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hoth Therapeutics does not currently pay a dividend.

Dividend Growth

Hoth Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.94% of the float of Hoth Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Hoth Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hoth Therapeutics has recently decreased by 16.16%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: -0.51

News Sentiment

Hoth Therapeutics has a news sentiment score of -0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Hoth Therapeutics this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for HOTH on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Hoth Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hoth Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.92% of the stock of Hoth Therapeutics is held by insiders.

Percentage Held by Institutions

Only 7.08% of the stock of Hoth Therapeutics is held by institutions.

HOTH Stock Analysis - Frequently Asked Questions

How have HOTH shares performed this year?

Hoth Therapeutics' stock was trading at $0.7481 at the start of the year. Since then, HOTH stock has increased by 77.8% and is now trading at $1.33.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.10.

When did Hoth Therapeutics' stock split?

Shares of Hoth Therapeutics reverse split on Wednesday, October 26th 2022.The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Hoth Therapeutics IPO?

Hoth Therapeutics (HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

Who are Hoth Therapeutics' major shareholders?

Hoth Therapeutics' top institutional investors include Geode Capital Management LLC (0.93%).
View institutional ownership trends.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hoth Therapeutics investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Meta Platforms (META), NVIDIA (NVDA) and Zomedica (ZOM).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HOTH
• CIK: 1711786
• Web: www.hoththerapeutics.com
• Phone: (646) 756-2997
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Hoth Therapeutics: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Potential Upside/Downside: +200.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -114.32%
• Return on Assets: -105.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.54
• Quick Ratio: 27.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.86 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 13,259,000
• Free Float: 12,341,000
• Market Cap: $17.63 million
• Optionable: Not Optionable
• Beta: 0.67